The House Energy and Commerce’s mark-up of user fee legislation for the US FDA on June 7 reflects lawmakers’ ongoing, laser-like focus on ensuring the key funding measure for the agency’s medical product review programs does not get bogged down in controversy.
The amended version of the FDA Reauthorization Act (FDARA) that passed the full committee on a 54-0 vote looks very...







